22 results on '"Pesenacker, Anne M."'
Search Results
2. T regulatory cell chemokine production mediates pathogenic T cell attraction and suppression
- Author
-
Patterson, Scott J., Pesenacker, Anne M., Wang, Adele Y., Gillies, Jana, Mojibian, Majid, Morishita, Kim, Tan, Rusung, Kieffer, Timothy J., Verchere, C. Bruce, Panagiotopoulos, Constadina, and Levings, Megan K.
- Subjects
T cells -- Research -- Physiological aspects ,Autoimmunity -- Research ,Health care industry - Abstract
T regulatory cells (Tregs) control immune homeostasis by preventing inappropriate responses to self and nonharmful foreign antigens. Tregs use multiple mechanisms to control immune responses, all of which require these cells to be near their targets of suppression; however, it is not known how Treg-to-target proximity is controlled. Here, we found that Tregs attract [CD4.sup.+] and [CD8.sup.+] T cells by producing chemokines. Specifically, Tregs produced both CCL3 and CCL4 in response to stimulation, and production of these chemokines was critical for migration of target T cells, as Tregs from [Ccl3.sup.-/-] mice, which are also deficient for CCL4 production, did not promote migration. Moreover, CCR5 expression by target T cells was required for migration of these cells to supernatants conditioned by Tregs. Tregs deficient for expression of CCL3 and CCL4 were impaired in their ability to suppress experimental autoimmune encephalomyelitis or islet allograft rejection in murine models. Moreover, Tregs from subjects with established type 1 diabetes were impaired in their ability to produce CCL3 and CCL4. Together, these results demonstrate a previously unappreciated facet of Treg function and suggest that chemokine secretion by Tregs is a fundamental aspect of their therapeutic effect in autoimmunity and transplantation., Introduction T regulatory cells (Tregs) are essential for preventing immunity to self antigens (Ags) and nonharmful foreign Ags; they also play an active role in suppressing immunity to tumors and [...]
- Published
- 2016
- Full Text
- View/download PDF
3. CD161 defines the subset of FoxP3+ T cells capable of producing proinflammatory cytokines
- Author
-
Pesenacker, Anne M., Bending, David, Ursu, Simona, Wu, Qiong, Nistala, Kiran, and Wedderburn, Lucy R.
- Published
- 2013
- Full Text
- View/download PDF
4. T Cell Expression of Granulocyte–Macrophage Colony-Stimulating Factor in Juvenile Arthritis Is Contingent Upon Th17 Plasticity
- Author
-
Piper, Christopher, Pesenacker, Anne M., Bending, David, Thirugnanabalan, Balathas, Varsani, Hemlata, Wedderburn, Lucy R., and Nistala, Kiran
- Published
- 2014
- Full Text
- View/download PDF
5. Immunological characteristics and T-cell receptor clonal diversity in children with systemic juvenile idiopathic arthritis undergoing T-cell-depleted autologous stem cell transplantation
- Author
-
Wu, Qiong, Pesenacker, Anne M., Stansfield, Alka, King, Douglas, Barge, Dawn, Foster, Helen E., Abinun, Mario, and Wedderburn, Lucy R.
- Published
- 2014
- Full Text
- View/download PDF
6. CD86 Is a Selective CD28 Ligand Supporting FoxP3+ Regulatory T Cell Homeostasis in the Presence of High Levels of CTLA-4.
- Author
-
Halliday, Neil, Williams, Cayman, Kennedy, Alan, Waters, Erin, Pesenacker, Anne M., Soskic, Blagoje, Hinze, Claudia, Hou, Tie Zheng, Rowshanravan, Behzad, Janman, Daniel, Walker, Lucy S. K., and Sansom, David M.
- Subjects
SUPPRESSOR cells ,CYTOTOXIC T lymphocyte-associated molecule-4 ,ANTIGEN presenting cells ,HOMEOSTASIS ,T cells - Abstract
CD80 and CD86 are expressed on antigen presenting cells and are required to engage their shared receptor, CD28, for the costimulation of CD4 T cells. It is unclear why two stimulatory ligands with overlapping roles have evolved. CD80 and CD86 also bind the regulatory molecule CTLA-4. We explored the role of CD80 and CD86 in the homeostasis and proliferation of CD4+FoxP3+ regulatory T cells (Treg), which constitutively express high levels of CTLA-4 yet are critically dependent upon CD28 signals. We observed that CD86 was the dominant ligand for Treg proliferation, survival, and maintenance of a regulatory phenotype, with higher expression of CTLA-4, ICOS, and OX40. We also explored whether CD80-CD28 interactions were specifically compromised by CTLA-4 and found that antibody blockade, clinical deficiency of CTLA-4 and CRISPR-Cas9 deletion of CTLA-4 all improved Treg survival following CD80 stimulation. Taken together, our data suggest that CD86 is the dominant costimulatory ligand for Treg homeostasis, despite its lower affinity for CD28, because CD80-CD28 interactions are selectively impaired by the high levels of CTLA-4. These data suggest a cell intrinsic role for CTLA-4 in regulating CD28 costimulation by direct competition for CD80, and indicate that that CD80 and CD86 have discrete roles in CD28 costimulation of CD4 T cells in the presence of high levels of CTLA-4. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
7. Characterization of regulatory T cells in obese omental adipose tissue in humans.
- Author
-
Wu, Dan, Han, Jonathan M., Yu, Xin, Lam, Avery J., Hoeppli, Romy E., Pesenacker, Anne M., Huang, Qing, Chen, Virginia, Speake, Cate, Yorke, Ekua, Nguyen, Nam, Sampath, Sharadh, Harris, David, and Levings, Megan K.
- Abstract
Obesity‐associated visceral adipose tissue (AT) inflammation promotes insulin resistance and type 2 diabetes (T2D). In mice, lean visceral AT is populated with anti‐inflammatory cells, notably regulatory T cells (Tregs) expressing the IL‐33 receptor ST2. Conversely, obese AT contains fewer Tregs and more proinflammatory cells. In humans, however, there is limited evidence for a similar pattern of obesity‐associated immunomodulation. We used flow cytometry and mRNA quantification to characterize human omental AT in 29 obese subjects, 18 of whom had T2D. Patients with T2D had increased proportions of inflammatory cells, including M1 macrophages, with positive correlations to body mass index. In contrast, Treg frequencies negatively correlated to body mass index but were comparable between T2D and non‐T2D individuals. Compared to human thymic Tregs, omental AT Tregs expressed similar levels of FOXP3, CD25, IKZF2, and CTLA4, but higher levels of PPARG, CCR4, PRDM1, and CXCL2. ST2, however, was not detectable on omental AT Tregs from lean or obese subjects. This is the first comprehensive investigation into how omental AT immunity changes with obesity and T2D in humans, revealing important similarities and differences to paradigms in mice. These data increase our understanding of how pathways of immune regulation could be targeted to ameliorate AT inflammation in humans. The proportion of regulatory T cells (Tregs) in human omental adipose tissue decreases in obesity. These human omental adipose Tregs exhibit a tissue‐specific phenotype but lack ST2 expression, in contrast to Tregs resident in mouse epididymal adipose tissue. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
8. An optimized method to measure human FOXP3+ regulatory T cells from multiple tissue types using mass cytometry.
- Author
-
Dawson, Nicholas A. J., Lam, Avery J., Cook, Laura, Hoeppli, Romy E., Broady, Raewyn, Pesenacker, Anne M., and Levings, Megan K.
- Published
- 2018
- Full Text
- View/download PDF
9. The role of FOXP3 in autoimmunity.
- Author
-
Pesenacker, Anne M, Cook, Laura, and Levings, Megan K
- Subjects
- *
SCURFIN (Protein) , *TYPE 1 diabetes , *AUTOIMMUNITY , *TRANSCRIPTION factors , *CELLULAR therapy - Abstract
FOXP3 controls the development and function of T regulatory cells (Tregs). Autoimmunity is linked to changes in FOXP3 activity that can occur at multiple levels and lead to Treg dysfunction. For example, changes in IL-2 signaling, FOXP3 transcription and/or post-translational modifications can all contribute to loss of self-tolerance. As additional pathways of FOXP3 regulation are elucidated, new therapeutic approaches to increase Treg activity either by cell therapy or pharmacological intervention are being tested. Early success from pioneering studies of Treg-based therapy in transplantation has promoted the undertaking of similar studies in autoimmunity, with emerging evidence for the effectiveness of these approaches, particularly in the context of type 1 diabetes. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
10. A Regulatory T-Cell Gene Signature Is a Specific and Sensitive Biomarker to Identify Children With New-Onset Type 1 Diabetes.
- Author
-
Pesenacker, Anne M., Wang, Adele Y., Singh, Amrit, Gillies, Jana, Youngwoong Kim, Piccirillo, Ciriaco A., Duc Nguyen, Haining, W. Nicholas, Tebbutt, Scott J., Panagiotopoulos, Constadina, Levings, Megan K., Kim, Youngwoong, and Nguyen, Duc
- Subjects
- *
TYPE 1 diabetes , *T cells , *GENES , *GENE expression , *BIOMARKERS , *AGE factors in disease , *CELL culture , *IMMUNITY , *MEDICAL screening , *RESEARCH funding , *CASE-control method , *DISEASE progression , *GENE expression profiling , *DIAGNOSIS - Abstract
Type 1 diabetes (T1D) is caused by immune-mediated destruction of insulin-producing β-cells. Insufficient control of autoreactive T cells by regulatory T cells (Tregs) is believed to contribute to disease pathogenesis, but changes in Treg function are difficult to quantify because of the lack of Treg-exclusive markers in humans and the complexity of functional experiments. We established a new way to track Tregs by using a gene signature that discriminates between Tregs and conventional T cells regardless of their activation states. The resulting 31-gene panel was validated with the NanoString nCounter platform and then measured in sorted CD4(+)CD25(hi)CD127(lo) Tregs from children with T1D and age-matched control subjects. By using biomarker discovery analysis, we found that expression of a combination of six genes, including TNFRSF1B (CD120b) and FOXP3, was significantly different between Tregs from subjects with new-onset T1D and control subjects, resulting in a sensitive (mean ± SD 0.86 ± 0.14) and specific (0.78 ± 0.18) biomarker algorithm. Thus, although the proportion of Tregs in peripheral blood is similar between children with T1D and control subjects, significant changes in gene expression can be detected early in disease process. These findings provide new insight into the mechanisms underlying the failure to control autoimmunity in T1D and might lead to a biomarker test to monitor Tregs throughout disease progression. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
11. Control of tissue-localized immune responses by human regulatory T cells.
- Author
-
Pesenacker, Anne M., Broady, Raewyn, and Levings, Megan K.
- Abstract
Treg cells control immune responses to self and nonharmful foreign antigens. Emerging data from animal models indicate that Treg cells function in both secondary lymphoid organs and tissues, and that these different microenvironments may contain specialized subsets of Treg cells with distinct mechanisms of action. The design of therapies for the restoration of tissue-localized immune homeostasis is dependent upon understanding how local immune responses are influenced by Treg cells in health versus disease. Here we review the current state of knowledge about human Treg cells in four locations: the skin, lung, intestine, and joint. Despite the distinct biology of these tissues, there are commonalities in the biology of their resident Treg cells, including phenotypic and functional differences from circulating Treg cells, and the presence of cytokine-producing (e.g. IL-17
+ ) FOXP3+ cells. We also highlight the challenges to studying tissue Treg cells in humans, and opportunities to use new technologies for the detailed analysis of Treg cells at the single-cell level. As emerging biological therapies are increasingly targeted toward tissue-specific effects, it is critical to understand their potential impact on local immune regulation. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
12. Hypomethylation at the Regulatory T Cell-Specific Demethylated Region in CD25hi T Cells Is Decoupled from FOXP3 Expression at the Inflamed Site in Childhood Arthritis.
- Author
-
Bending, David, Pesenacker, Anne M., Ursu, Simona, Qiong Wu, Hannah Lom, Thirugnanabalan, Balathas, and Wedderburn, Lucy R.
- Subjects
- *
METHYLATION , *T cell receptors , *DELSARTE system , *INFLAMMATION , *RHEUMATISM - Abstract
The maintenance of FOXP3 expression in CD25hi regulatory T cells (Tregs) is crucial to the control of inflammation and essential for successful Treg transfer therapies. Coexpression of CD25 and FOXP3 in combination with a hypomethylated region within the FOXP3 gene, called the Treg-specific demethylated region (TSDR), is considered the hallmark of stable Tregs. The TSDR is an epigenetic motif that is important for stable FOXP3 expression and is used as a biomarker to measure Treg lineage commitment. In this study, we report that, unlike in peripheral blood, CD4+ T cell expression of CD25 and FOXP3 is frequently dissociated at the inflamed site in patients with juvenile idiopathic arthritis, which led us to question the stability of human Tregs in chronic inflammatory environments. We describe a novel CD4+CD127loCD25hi human T cell population that exhibits extensive TSDR and promoter demethylation in the absence of stable FOXP3 expression. This population expresses high levels of CTLA-4 and can suppress T conventional cell proliferation in vitro. These data collectively suggest that this population may represent a chronically activated FOXP3lo Treg population. We show that these cells have defects in IL-2 signaling and reduced expression of a deubiquitinase important for FOXP3 stability. Clinically, the proportions of these cells within the CD25hi T cell subset are increased in patients with the more severe courses of disease. Our study demonstrates, therefore, that hypomethylation at the TSDR can be decoupled from FOXP3 expression in human T cells and that environment-specific breakdown in FOXP3 stability may compromise the resolution of inflammation in juvenile idiopathic arthritis. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
13. Optimized CRISPR-mediated gene knockin reveals FOXP3-independent maintenance of human Treg identity.
- Author
-
Lam, Avery J., Lin, David T.S., Gillies, Jana K., Uday, Prakruti, Pesenacker, Anne M., Kobor, Michael S., and Levings, Megan K.
- Abstract
Regulatory T cell (Treg) therapy is a promising curative approach for a variety of immune-mediated conditions. CRISPR-based genome editing allows precise insertion of transgenes through homology-directed repair, but its use in human Tregs has been limited. We report an optimized protocol for CRISPR-mediated gene knockin in human Tregs with high-yield expansion. To establish a benchmark of human Treg dysfunction, we target the master transcription factor FOXP3 in naive and memory Tregs. Although FOXP3-ablated Tregs upregulate cytokine expression, effects on suppressive capacity in vitro manifest slowly and primarily in memory Tregs. Moreover, FOXP3-ablated Tregs retain their characteristic protein, transcriptional, and DNA methylation profile. Instead, FOXP3 maintains DNA methylation at regions enriched for AP-1 binding sites. Thus, although FOXP3 is important for human Treg development, it has a limited role in maintaining mature Treg identity. Optimized gene knockin with human Tregs will enable mechanistic studies and the development of tailored, next-generation Treg cell therapies. [Display omitted] • Optimized method for human Treg expansion with CRISPR-mediated gene knockin • FOXP3 ablation causes more pronounced defects in memory Tregs than naive Tregs • FOXP3-KO Tregs retain a Treg-type protein, transcript, and DNA methylation profile • FOXP3 maintains DNA methylation at regions enriched for AP-1 binding sites Lam et al. optimize efficient CRISPR-based targeted gene integration in naive and memory human Tregs. Using this method, the authors find FOXP3 has subset-specific roles in regulating mature Treg function and a limited role in maintaining lineage identity. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
14. Innate Control of Tissue-Reparative Human Regulatory T Cells.
- Author
-
Lam, Avery J., MacDonald, Katherine N., Pesenacker, Anne M., Juvet, Stephen C., Morishita, Kimberly A., Bressler, Brian, Pan, James G., Sidhu, Sachdev S., Rioux, John D., and Levings, Megan K.
- Subjects
- *
HUMAN T cells , *SYNOVIAL fluid , *GROWTH factors , *CELLULAR therapy , *T cells - Abstract
Regulatory T cell (Treg) therapy is a potential curative approach for a variety of immune-mediated conditions, including autoimmunity and transplantation, in which there is pathological tissue damage. In mice, IL-33R (ST2)--expressing Tregs mediate tissue repair by producing the growth factor amphiregulin, but whether similar tissue-reparative Tregs exist in humans remains unclear. We show that human Tregs in blood and multiple tissue types produced amphiregulin, but this was neither a unique feature of Tregs nor selectively upregulated in tissues. Human Tregs in blood, tonsil, synovial fluid, colon, and lung tissues did not express ST2, so ST2+ Tregs were engineered via lentiviral-mediated overexpression, and their therapeutic potential for cell therapy was examined. Engineered ST2+ Tregs exhibited TCR-independent, IL-33--stimulated amphiregulin expression and a heightened ability to induce M2-like macrophages. The finding that amphiregulin-producing Tregs have a noneffector phenotype and are progressively lost upon TCR-induced proliferation and differentiation suggests that the tissue repair capacity of human Tregs may be an innate function that operates independently from their classical suppressive function. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
15. The immune landscape of the inflamed joint defined by spectral flow cytometry.
- Author
-
Attrill MH, Shinko D, Alexiou V, Kartawinata M, Study CHARMS, Study JIAP, Wedderburn LR, and Pesenacker AM
- Abstract
Cellular phenotype and function are altered in different microenvironments. For targeted therapies it is important to understand site-specific cellular adaptations. Juvenile Idiopathic Arthritis (JIA) is characterised by autoimmune joint inflammation, with frequent inadequate treatment responses. To comprehensively assess the inflammatory immune landscape, we designed a 37-parameter spectral flow cytometry panel delineating mononuclear cells from JIA synovial fluid (SF) of autoimmune inflamed joints, compared to JIA and healthy control blood. Synovial monocytes and NK cells (CD56bright) lack Fc-receptor CD16, suggesting antibody-mediated targeting may be ineffective. B cells and DCs, both in small frequencies in SF, undergo maturation with high 4-1BB, CD71, CD39 expression, supporting T cell activation. SF effector and regulatory T cells were highly active with newly described co-receptor combinations that may alter function, and suggestion of metabolic reprogramming via CD71, TNFR2 and PD-1. Most SF effector phenotypes, as well as an identified CD4-Foxp3+ T cell population, were restricted to the inflamed joint, yet specific SF-predominant CD4+Foxp3+ Treg subpopulations were increased in blood of active but not inactive JIA, suggesting possible recirculation and loss of immunoregulation at distal sites. This first comprehensive dataset of the site-specific inflammatory landscape at protein level will inform functional studies and the development of targeted therapeutics to restore immunoregulatory balance and achieve remission in JIA., (© The Author(s) 2024. Published by Oxford University Press on behalf of the British Society for Immunology.)
- Published
- 2024
- Full Text
- View/download PDF
16. A phase 1b open-label dose-finding study of ustekinumab in young adults with type 1 diabetes.
- Author
-
Marwaha AK, Chow S, Pesenacker AM, Cook L, Sun A, Long SA, Yang JHM, Ward-Hartstonge KA, Williams E, Domingo-Vila C, Halani K, Harris KM, Tree TIM, Levings MK, Elliott T, Tan R, and Dutz JP
- Abstract
Objectives: We assessed the safety of ustekinumab (a monoclonal antibody used in psoriasis to target the IL-12 and IL-23 pathways) in a small cohort of recent-onset (<100 days of diagnosis) adults with type 1 diabetes (T1D) by conducting a pilot open-label dose-finding and mechanistic study (NCT02117765) at the University of British Columbia., Methods: We sequentially enrolled 20 participants into four subcutaneous dosing cohorts: (i) 45 mg loading weeks 0/4/16, (ii) 45 mg maintenance weeks 0/4/16/28/40, (iii) 90 mg loading weeks 0/4/16, and (iv) 90 mg maintenance weeks 0/4/16/28/40. The primary endpoint was safety as assessed by an independent data and safety monitoring board (DSMB) but we also measured mixed meal tolerance test C-peptide, insulin use/kg, and HbA1c. Immunophenotyping was performed to assess immune cell subsets and islet antigen-specific T cell responses., Results: Although several adverse events were reported, only two (bacterial vaginosis and hallucinations) were thought to be possibly related to drug administration by the study investigators. At 1 year, the 90 mg maintenance dosing cohort had the smallest mean decline in C-peptide area under the curve (AUC) (0.1 pmol/ml). Immunophenotyping showed that ustekinumab reduced the percentage of circulating Th17, Th1, and Th17.1 cells and proinsulin-specific T cells that secreted IFN-γ and IL-17A., Conclusion: Ustekinumab was deemed safe to progress to efficacy studies by the DSMB at doses used to treat psoriasis in adults with T1D. A 90 mg maintenance dosing schedule reduced proinsulin-specific IFN-γ and IL-17A-producing T cells. Further studies are warranted to determine if ustekinumab can prevent C-peptide AUC decline and induce a clinical response., (© The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Immunology.)
- Published
- 2021
- Full Text
- View/download PDF
17. A composite immune signature parallels disease progression across T1D subjects.
- Author
-
Speake C, Skinner SO, Berel D, Whalen E, Dufort MJ, Young WC, Odegard JM, Pesenacker AM, Gorus FK, James EA, Levings MK, Linsley PS, Akirav EM, Pugliese A, Hessner MJ, Nepom GT, Gottardo R, and Long SA
- Subjects
- Adolescent, Adult, Child, Computational Biology, Female, Humans, Hypoglycemic Agents pharmacology, Immunotherapy methods, Insulin-Secreting Cells metabolism, Male, Young Adult, Diabetes Mellitus, Type 1 drug therapy, Diabetes Mellitus, Type 1 immunology, Disease Progression, Insulin Secretion physiology
- Abstract
At diagnosis, most people with type 1 diabetes (T1D) produce measurable levels of endogenous insulin, but the rate at which insulin secretion declines is heterogeneous. To explain this heterogeneity, we sought to identify a composite signature predictive of insulin secretion, using a collaborative assay evaluation and analysis pipeline that incorporated multiple cellular and serum measures reflecting β cell health and immune system activity. The ability to predict decline in insulin secretion would be useful for patient stratification for clinical trial enrollment or therapeutic selection. Analytes from 12 qualified assays were measured in shared samples from subjects newly diagnosed with T1D. We developed a computational tool (DIFAcTO, Data Integration Flexible to Account for different Types of data and Outcomes) to identify a composite panel associated with decline in insulin secretion over 2 years following diagnosis. DIFAcTO uses multiple filtering steps to reduce data dimensionality, incorporates error estimation techniques including cross-validation and sensitivity analysis, and is flexible to assay type, clinical outcome, and disease setting. Using this novel analytical tool, we identified a panel of immune markers that, in combination, are highly associated with loss of insulin secretion. The methods used here represent a potentially novel process for identifying combined immune signatures that predict outcomes relevant for complex and heterogeneous diseases like T1D.
- Published
- 2019
- Full Text
- View/download PDF
18. Treg gene signatures predict and measure type 1 diabetes trajectory.
- Author
-
Pesenacker AM, Chen V, Gillies J, Speake C, Marwaha AK, Sun A, Chow S, Tan R, Elliott T, Dutz JP, Tebbutt SJ, and Levings MK
- Subjects
- Adolescent, Adult, Algorithms, Canada, Computational Biology, Cross-Sectional Studies, Diabetes Mellitus, Type 1 genetics, Diabetes Mellitus, Type 1 therapy, Diabetes Mellitus, Type 2, Gene Expression Regulation, Genotype, Humans, Immunotherapy, Leukocytes, Mononuclear, RNA, Messenger metabolism, Young Adult, Biomarkers analysis, Diabetes Mellitus, Type 1 immunology, T-Lymphocytes, Regulatory immunology
- Abstract
Background: Multiple therapeutic strategies to restore immune regulation and slow type 1 diabetes (T1D) progression are in development and testing. A major challenge has been defining biomarkers to prospectively identify subjects likely to benefit from immunotherapy and/or measure intervention effects. We previously found that, compared with healthy controls, Tregs from children with new-onset T1D have an altered Treg gene signature (TGS), suggesting that this could be an immunoregulatory biomarker., Methods: nanoString was used to assess the TGS in sorted Tregs (CD4+CD25hiCD127lo) or peripheral blood mononuclear cells (PBMCs) from individuals with T1D or type 2 diabetes, healthy controls, or T1D recipients of immunotherapy. Biomarker discovery pipelines were developed and applied to various sample group comparisons., Results: Compared with controls, the TGS in isolated Tregs or PBMCs was altered in adult new-onset and cross-sectional T1D cohorts, with sensitivity or specificity of biomarkers increased by including T1D-associated SNPs in algorithms. The TGS was distinct in T1D versus type 2 diabetes, indicating disease-specific alterations. TGS measurement at the time of T1D onset revealed an algorithm that accurately predicted future rapid versus slow C-peptide decline, as determined by longitudinal analysis of placebo arms of START and T1DAL trials. The same algorithm stratified participants in a phase I/II clinical trial of ustekinumab (αIL-12/23p40) for future rapid versus slow C-peptide decline., Conclusion: These data suggest that biomarkers based on measuring TGSs could be a new approach to stratify patients and monitor autoimmune activity in T1D., Funding: JDRF (1-PNF-2015-113-Q-R, 2-PAR-2015-123-Q-R, 3-SRA-2016-209-Q-R, 3-PDF-2014-217-A-N), the JDRF Canadian Clinical Trials Network, the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (UM1AI109565 and FY15ITN168), and BCCHRI.
- Published
- 2019
- Full Text
- View/download PDF
19. Targeting Tregs in Juvenile Idiopathic Arthritis and Juvenile Dermatomyositis-Insights From Other Diseases.
- Author
-
Hoeppli RE and Pesenacker AM
- Subjects
- Animals, Antibodies, Monoclonal, Humanized pharmacology, Antibodies, Monoclonal, Humanized therapeutic use, Autoimmunity, Biomarkers, Cytokines antagonists & inhibitors, Humans, Mice, Treatment Outcome, Arthritis, Juvenile immunology, Arthritis, Juvenile therapy, Dermatomyositis immunology, Dermatomyositis therapy, Immunotherapy, Adoptive adverse effects, T-Lymphocytes, Regulatory immunology
- Abstract
Regulatory T cells (Tregs) are believed to be dysfunctional in autoimmunity. Juvenile idiopathic arthritis (JIA) and juvenile dermatomyositis (JDM) result from a loss of normal immune regulation in specific tissues such as joints or muscle and skin, respectively. Here, we discuss recent findings in regard to Treg biology in oligo-/polyarticular JIA and JDM, as well as what we can learn about Treg-related disease mechanism, treatment and biomarkers in JIA/JDM from studies of other diseases. We explore the potential use of Treg immunoregulatory markers and gene signatures as biomarkers for disease course and/or treatment success. Further, we discuss how Tregs are affected by several treatment strategies already employed in the therapy of JIA and JDM and by alternative immunotherapies such as anti-cytokine or co-receptor targeting. Finally, we review recent successes in using Tregs as a treatment target with low-dose IL-2 or cellular immunotherapy. Thus, this mini review will highlight our current understanding and identify open questions in regard to Treg biology, and how recent findings may advance biomarkers and new therapies for JIA and JDM.
- Published
- 2019
- Full Text
- View/download PDF
20. An optimized method to measure human FOXP3 + regulatory T cells from multiple tissue types using mass cytometry.
- Author
-
Dawson NAJ, Lam AJ, Cook L, Hoeppli RE, Broady R, Pesenacker AM, and Levings MK
- Subjects
- Antigens immunology, Humans, Staining and Labeling methods, T-Lymphocytes, Regulatory immunology, CD4 Lymphocyte Count methods, Flow Cytometry methods, Forkhead Transcription Factors metabolism, T-Lymphocytes, Regulatory cytology
- Abstract
We optimized a method to detect FOXP3 by mass cytometry and compared the resulting data to conventional flow cytometry. We also demonstrated the utility of the protocol to profile antigen-specific Tregs from whole blood, or Tregs from tissues such as cord blood, thymus and synovial fluid., (© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.)
- Published
- 2018
- Full Text
- View/download PDF
21. Hypomethylation at the regulatory T cell-specific demethylated region in CD25hi T cells is decoupled from FOXP3 expression at the inflamed site in childhood arthritis.
- Author
-
Bending D, Pesenacker AM, Ursu S, Wu Q, Lom H, Thirugnanabalan B, and Wedderburn LR
- Subjects
- Adult, Biomarkers, CTLA-4 Antigen biosynthesis, Cell Proliferation, Child, Female, Humans, Inflammation immunology, Interferon-gamma biosynthesis, Interleukin-17 biosynthesis, Interleukin-2 immunology, Interleukin-2 Receptor alpha Subunit chemistry, Male, Methylation, Signal Transduction immunology, T-Lymphocytes, Regulatory cytology, Tumor Necrosis Factor-alpha biosynthesis, Ubiquitin-Specific Proteases genetics, Arthritis, Juvenile immunology, Forkhead Transcription Factors biosynthesis, Interleukin-2 Receptor alpha Subunit biosynthesis, T-Lymphocytes, Regulatory immunology
- Abstract
The maintenance of FOXP3 expression in CD25(hi) regulatory T cells (Tregs) is crucial to the control of inflammation and essential for successful Treg transfer therapies. Coexpression of CD25 and FOXP3 in combination with a hypomethylated region within the FOXP3 gene, called the Treg-specific demethylated region (TSDR), is considered the hallmark of stable Tregs. The TSDR is an epigenetic motif that is important for stable FOXP3 expression and is used as a biomarker to measure Treg lineage commitment. In this study, we report that, unlike in peripheral blood, CD4(+) T cell expression of CD25 and FOXP3 is frequently dissociated at the inflamed site in patients with juvenile idiopathic arthritis, which led us to question the stability of human Tregs in chronic inflammatory environments. We describe a novel CD4(+)CD127(lo)CD25(hi) human T cell population that exhibits extensive TSDR and promoter demethylation in the absence of stable FOXP3 expression. This population expresses high levels of CTLA-4 and can suppress T conventional cell proliferation in vitro. These data collectively suggest that this population may represent a chronically activated FOXP3(lo) Treg population. We show that these cells have defects in IL-2 signaling and reduced expression of a deubiquitinase important for FOXP3 stability. Clinically, the proportions of these cells within the CD25(hi) T cell subset are increased in patients with the more severe courses of disease. Our study demonstrates, therefore, that hypomethylation at the TSDR can be decoupled from FOXP3 expression in human T cells and that environment-specific breakdown in FOXP3 stability may compromise the resolution of inflammation in juvenile idiopathic arthritis., (Copyright © 2014 The Authors.)
- Published
- 2014
- Full Text
- View/download PDF
22. T regulatory cells in childhood arthritis--novel insights.
- Author
-
Pesenacker AM and Wedderburn LR
- Subjects
- Adolescent, Adoptive Transfer, Animals, Arthritis, Juvenile metabolism, Arthritis, Juvenile therapy, Child, Cytokines genetics, Cytokines metabolism, Humans, T-Lymphocytes, Regulatory classification, T-Lymphocytes, Regulatory metabolism, Arthritis, Juvenile immunology, T-Lymphocytes, Regulatory immunology
- Abstract
In recent years, there have been many new developments in the field of regulatory T cells (Treg), challenging the consensus on their behaviour, classification and role(s) in disease. The role Treg might play in autoimmune disease appears to be more complex than previously thought. Here, we discuss the current knowledge of regulatory T cells through animal and human research and illustrate the recent developments in childhood autoimmune arthritis (juvenile idiopathic arthritis (JIA)). Furthermore, this review summarises our understanding of the fields and assesses current and future implications for Treg in the treatment of JIA.
- Published
- 2013
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.